Navigation Links
New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Date:10/11/2007

HAYWARD, Calif., Oct. 11 /PRNewswire/ -- Guava Technologies today launched a new corporate website with an infrastructure focused around its main audiences: Life Scientists, Flow Cytometrists, and Clinicians.

With flow cytometry being an essential tool for cell analysis, Guava Technologies is dedicated to finding innovative ways to make the technology as practical as possible for all life scientists and clinicians who work with cells. This dedication is obvious from the audience-centric organization of the new site, where the main choices on the home page for further investigation are targeted to the unique needs of the company's main markets: Life Science Research (i.e., pharma/biotech, academia/government, clinical research), Flow Cytometry, and Clinical Diagnostics.

While the website does offer traditional navigation, those links are secondary. The site is obviously built around the company's desire to serve its key market segments and stakeholders. According to Lawrence Bruder, CEO, the audience-centric organization was the obvious choice from the beginning: "Those individuals are the reason we are in business; the reason our employees come to work every day," said Mr. Bruder, "so given the importance of our website as a vehicle for two-way communication with them, it just made sense to focus it on their needs."

Guava Technologies encourages everyone interested in flow cytometry or the company to visit the site at http://www.guavatechnologies.com, and to let the company know what it can do to further improve the site based on their needs and interests.

Guava Technologies is a private biotechnology and medical device company. In 2001, it introduced the first commercial benchtop microcapillary flow cytometer with easy-to-use, assay-specific reagents and software. Since then, it has introduced numerous new systems and assays, always focusing on making flow cytometry more practical for life scientists and clinicians. Guava Systems do not require sheath fluid so accommodate smaller sample volumes, generate less waste, have lower daily operate costs, and are easier to set-up and maintain than traditional flow cytometers. And, all Guava Systems perform direct, absolute cell counts without reference beads. True to the company's goal, virtually any scientist or clinician can learn to operate a Guava System in less than one day.


'/>"/>
SOURCE Guava Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Selecting siRNA Sequences to Incorporate into the pSilencer Vectors
2. Pre-eminent, web-based companies owe success to corporate venturing
3. Corporate Social Responsibility - Burden, sham, or golden opportunity?
4. Corporate venturing can nurture software success
5. Enrons dilemma: A corporate governance nightmare
6. Getting beyond the vortex of corporate mediocrity
7. Corporate control begins with a strong board
8. Directors more assertive in corporate governance
9. The black hole of corporate branding
10. Corporate Americas hidden deficit
11. Business professor launches corporate reporting study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):